Fig. 1. Trial profile. From: Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the.

Slides:

Advertisements

Similar presentations

Chapter 85 Chapter 85 Parathyroid Hormone Treatment for Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.

Advertisements

Downloaded from 1 Alendronate vs. Risedronate Comparison Trial.

Slide 1 Update on Alendronate and Raloxifene in Osteoporosis EFficacy of FOSALAN ™ vs. Evista ® Comparison Trial (EFFECT) FOSALAN (alendronate) is a trademark.

Protelos Long-Term Antifracture Efficacy. Protelos Vertebral Antifracture Efficacy over 4 years in SOTI Favors Protelos  RR P

Relationship of Drug Associated Change in Bone Mineral Density to Fracture Risk Marc C. Hochberg, MD, MPH FDA Endocrinologic and Metabolic Drugs Advisory.

Treatment. Bisphosphonates Promotes bone formation and decreases bone resorption Mechanism of Action First line treatment for osteoporosis in both men.

ECTS symposium 5 Anabolic treatment of osteoporosis.

1 Ipriflavone in the Treatment of Postmenopausal Osteoporosis Randomized placebo-controlled, 4-year study conducted Europe 475 postmenopausal white women,

TERIPARATIDE (r-hPTH 1-34) Endocrinologic and Metabolic Drugs Advisory Committee Holiday Inn, Bethesda MD July 27, 2001 Bruce S. Schneider, MD CDER FDA.

Chapter 83 Chapter 83 Denosumab for the Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.

Download from Slide 1 Update on Alendronate and Raloxifene in Osteoporosis EFficacy of Fosamax ™ vs. Evista ® Comparison.

T.S. Tran, J.R. Center, M.J. Seibel, J.A. Eisman,

Extended Treatment Effects with Zoledronic Acid Based on Poster 1070 “The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment in Osteoporosis: a Randomized.

Chapter 72 Chapter 72 Calcium in the Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.

Estrogen plus Progestin, BMD and Fractures: Women’s Health Initiative Jane A. Cauley University of Pittsburgh JAMA 2003; 290 (13) :

FDA’s Osteoporosis Guidance Center for Drug Evaluation and Research Division of Metabolic and Endocrine Drugs Eric Colman, MD September 25, 2002.

Ten Years’ Experience with Alendronate for the Treatment of Osteoporosis in Postmenopausal Women Adapted from Bone HG, Hosking D, Devogelaer J-P, Tucci.

Chapter 41: Role of Sex Steroids in the Pathogenesis of Osteoporosis Matthew T. Drake and Sundeep Khosla.

Chapter 34: Biochemical Markers of Bone Turnover in Osteoporosis Pawel Szulc and Pierre D. Delmas.

Osteopenia and Osteoporosis

Date of download: 7/6/2016 From: Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial Ann Intern Med. 2015;162(12):

Figure 2. Summary of trial events

Therapeutic Implications

Fig. 1. Baseline and 3-month infusion protocol

Volume 48, Issue 4, Pages (April 2011)

Anti-Osteoporotic drugs Old & New

Fig. 1. Time line for investigations

Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis Peyman Hadji Critical Reviews in Oncology.

Chapter 61: Transplantation Osteoporosis

Fig. 1. Mean BMI and BMI Z-score (se) of the children with AA, TA, and TT genotypes in rs of the FTO gene. The P values are for the additive model.

Fig. 1. Correlation of TSH with TC, LDL-C, HDL-C, and TG.

Figure 2 Top panel shows mean (SE) differences in near-final height (cm) (n = 71) in the AI, GH, and AI/GH groups regardless of length of treatment (n.

Fig. 1. Study enrollment and disposition of participants

Figure 1. Illustrative 24-h serum LH concentration (IRMA) profiles and calculated LH secretory rates as determined by deconvolution analysis in one healthy.

Fig. 2. Plasma melatonin secretion profiles for each of the eight subjects across the three conditions in the study. Profiles are shown for the entire.

3Biostatistics, Pacific University, Forest Grove, Oregon, USA

Figure 1. Consort flow diagram.

Fig. 1. BAT activity before and after WL

Fig. 1. Flow of subjects through different phases of the study.

Fig. 1. Distribution of tetracycline labels (A) and MS/BS (B) in the TPTD and ZOL acid groups: values are medians (interquartile range). Representative.

Fig. 1. Active GLP-1 and total PYY in response to a liquid test meal

From: Low Vitamin D Status despite Abundant Sun Exposure

Figure 1. Serum B-ALP levels in normal male (•) and female (○) children as a function of age. Serum B-ALP levels were increased during infancy and puberty.

Figure 1. Total (A) and free (B) T, estradiol (C), and SHBG (D) levels at baseline and during treatment. From: Testosterone Treatment and Sexual Function.

Fig. 5. Histopathological study of the tumor tissue removed from patient 2. A, Macroscopic view of a tumor slice showing a dense tissue occupying the center.

(Modified from Conlin PR, et al

Effects of various bisphosphonates on clinical vertebral fractures (A), nonvertebral fractures (B), and hip fractures (C). PLB, placebo; RRR, relative.

Figure 1. Summary of PTH secretion from human parathyroid cells after caffeine treatment at concentrations of 0, 1, 10, and 50 μm at extracellular calcium.

Predicted values and SEs were based on linear mixed models

FIG. 1 Odds ratios (95% CIs) of metabolic syndrome and individual components calculated for clinical measures of periodontal disease (A and B). For gingival.

Fig. 3. Mean body weight of women randomized to low-carbohydrate and low-fat diets over the course of the 4-month trial. The first time point (wk 1) represents.

Figure 1. Height distribution for adults with AIS.

From: Is Age a Risk Factor for Hypothyroidism in Pregnancy

Triangles and dotted lines are for mean values. , P <

Fig. 4. Relationships of changes in CRP or SAA to changes in body weight and insulin resistance. For each comparison the regression line is shown (solid.

Fig. 1. Serum levels of IGF-I vs

Osteoporosis Diagnosis 9/21/2018 OSTEOPOROSIS.

The Future of Osteoporosis: Improving Care Along the Way

Diabetes and Bone: the model of GIO

Deciding on Pharmacological Treatment Post Fracture

Risk Factors for the Development of Bone Metastases in Prostate Cancer

Vert Non-Vert Hip ** ** Zoledronic Acid3 Zoledronic Acid4 Denosumab5

Deciding on Pharmacological Treatment Post Fracture

Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis

Serum osteocalcin and procollagen as markers for the risk of osteoporotic fracture in corticosteroid-treated asthmatic adults John H. Toogood, MD, FRCPCa,b,

Comparison of NRTI combinations

Volume 56, Issue 3, Pages (September 1999)

Enrollment and Outcomes

Figure 1. Relative risks of vertebral, hip, and nonvertebral fractures (and 95% CIs) in response to the treatments for ... Figure 1. Relative risks of.

Subjects Randomized to Denosumab or Bisphosphonate Therapy

Presentation transcript:

Fig. 1. Trial profile. From: Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk J Clin Endocrinol Metab. 2012;97(9):3097-3106. doi:10.1210/jc.2011-3479 J Clin Endocrinol Metab | Copyright © 2012 by The Endocrine Society

Fig. 2. Incidence of new fractures during the 72-wk study period was confirmed by radiology. A, Kaplan-Meier method, statistical significance assessed by a log-rank test. RR, Relative risk. B, Incidence values of new vertebral fractures assessed every 24 wk by Fisher's exact test. 95% CI is presented for the results of fracture incidences. C, Incidences of clinical fragility fracture in the teriparatide group were significantly reduced compared with placebo. From: Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk J Clin Endocrinol Metab. 2012;97(9):3097-3106. doi:10.1210/jc.2011-3479 J Clin Endocrinol Metab | Copyright © 2012 by The Endocrine Society

Fig. 3. Changes over time in BMD and biochemical markers Fig. 3. Changes over time in BMD and biochemical markers. For the BMD analysis, the difference in percentage changes from baseline was compared between the teriparatide and placebo groups for the bone turnover markers. A, Lumbar spine BMD; B, total hip BMD; C, serum osteocalcin; D, serum P1NP; E, u-NTX; and F, corrected serum calcium. A comparison was performed using a paired t test with the Wilcoxon test; bars indicate 95% CI. From: Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk J Clin Endocrinol Metab. 2012;97(9):3097-3106. doi:10.1210/jc.2011-3479 J Clin Endocrinol Metab | Copyright © 2012 by The Endocrine Society